Study | Vaccine/(adjuvant) | Target subjects | Clinical trial | Results |
---|---|---|---|---|
[104] | Monomeric gp350/(MPL) | 181 EBV-seronegative young adults | Phase II | Efficacy: 78%; neutralizing antibodies was induced up to 18Â months, but no prevention against asymptomatic EBV infection |
[105] | Monomeric gp350/(alhydrogel) | 16 EBV-negative children with CKD, candidates of renal transplantation | Phase I | 13 recipients had IgG response; only 4 recipients induced neutralizing antibodies but immune response declined rapidly. Poor immunogenicity against PTLD protection |
[106] | Trimeric gH/gL and gB/(alum + CpG-ODN) | Rabbit | – | Potent EBV-neutralizing titers induced, neutralizing titre were  > 100-fold than monomeric gp350  > 20-fold than monomeric gh/gL  > 18-fold than trimeric gB, and  > fourfold than tetrameric gp350 |
[107] | Chimeric VLP: EBV gp350/220 | BALB/c mice | – | Long-term neutralizing antibodies was induced |
[108] | Packaging cell line VLP: modified EBV genome with deletion of TR | Epithelial cell line | – | Able to target B-cell in vitro, unwanted recombinant DNA was performed |
[109] | Packaging cell line VLP: modified EBV genome with inactivation of six viral genes | 293-VII + producer cell line, and BALB/c mice | – | High immunogenicity, induced potent neutralizing polyvalent antibodies and T-cells responses in vitro and in vivo models |
[110] | Latent protein as vaccine candidates: CD8+ T-cell peptide Epitope-based/(water-in-oil emulsion) | 14 HLA B*0801 positive, EBV-seronegative adults | Phase I | 1/2 placebo recipients acquired developed IM 4/4 peptide recipients acquired asymptomatic EBV infection |